Ligand Pharmaceuticals Inc.  

(Public, NASDAQ:LGND)   Watch this stock  
Find more results for LGND
49.17
-2.00 (-3.91%)
After Hours: 49.17 0.00 (0.00%)
Jul 31, 5:04PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 48.92 - 51.67
52 week 36.82 - 80.42
Open 50.42
Vol / Avg. 273,638.00/394,444.00
Mkt cap 1.02B
P/E 106.67
Div/yield     -
EPS 0.46
Shares 20.73M
Beta 1.26
Inst. own 102%
Aug 4, 2014
Q2 2014 Ligand Pharmaceuticals, Inc. Earnings Release - 9:30AM EDT - Add to calendar
Aug 4, 2014
Q2 2014 Ligand Pharmaceuticals Inc Earnings Call - 9:00AM EDT - Add to calendar
Jun 24, 2014
Ligand Pharmaceuticals Inc at ROTH Healthcare Corporate Access Day
Jun 4, 2014
Ligand Pharmaceuticals, Inc. Annual Shareholder Meeting
May 28, 2014
Ligand Pharmaceuticals, Inc. at Craig-Hallum Institutional Investor Conference
May 13, 2014
Ligand Pharmaceuticals, Inc. at Bank of America Merrill Lynch Health Care Conference
May 7, 2014
Ligand Pharmaceuticals, Inc. at Deutsche Bank Healthcare Conference
May 7, 2014
Q1 2014 Ligand Pharmaceuticals, Inc. Earnings Release
May 7, 2014
Q1 2014 Ligand Pharmaceuticals, Inc. Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 13.14% 18.03%
Operating margin 31.96% 30.51%
EBITD margin - 38.15%
Return on average assets 8.00% 8.45%
Return on average equity 14.68% 23.21%
Employees 20 -
CDP Score - -

Address

Suite 200, 11119 North Torrey Pines Road
LA JOLLA, CA 92037
United States - Map
+1-858-5507500 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring assets. The Company�s technology portfolio CAPTISOL is a formulation technology that has enabled five Food and Drug Administration (FDA) approved products, including Pfizer�s VFEND IV and Baxter International�s Nexterone and is being used in a number of clinical-stage partner programs. The therapies in its portfolio in development address the unmet medical needs of patients for a spectrum of diseases, including hepatitis, muscle wasting, Alzheimer�s disease, dyslipidemia, diabetes, anemia, asthma, rheumatoid arthritis and osteoporosis. It�s wholly owned subsidiaries include Ligand JVR, Allergan Ligand Retinoid Therapeutics, Seragen, Inc., Pharmacopeia, LLC, Neurogen Corporation, CyDex Pharmaceuticals, Inc. and Metabasis Therapeutics. On January 26, 2011, the Company acquired CyDex Pharmaceuticals, Inc. (CyDex).

Officers and directors

John W. Kozarich Ph.D. Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
John L. Higgins President, Chief Executive Officer, Director
Age: 44
Bio & Compensation  - Reuters
Nishan de Silva M.D. Chief Financial Officer, Vice President - Finance and Strategy
Age: 41
Bio & Compensation  - Reuters
Matthew W. Foehr Chief Operating Officer, Executive Vice President
Age: 41
Bio & Compensation  - Reuters
Charles S. Berkman J.D. Vice President, General Counsel, Secretary
Age: 45
Bio & Compensation  - Reuters
Jason M. Aryeh Independent Director
Age: 45
Bio & Compensation  - Reuters
Todd C. Davis Independent Director
Age: 53
Bio & Compensation  - Reuters
David M. Knott Independent Director
Age: 69
Bio & Compensation  - Reuters
John L. LaMattina Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Sunil Patel Independent Director
Age: 42
Bio & Compensation  - Reuters